Accessibility Menu
Dermisonics logo

Dermisonics(OTC) DMSI

Market Cap$800.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year+1,200%
1 Year+1,200%
1 Month+1,200%
$0.00
+0.00%
+0.00Today
Dermisonics last closing stock price
MetricPriceDate
Last closeUSD 0.002025-11-03
Dermisonics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1,200%USD 0.002024-11-20
1 month+1,200%USD 0.002024-11-20
3 month+1,200%USD 0.002024-11-20
Year to date+1,200%USD 0.002024-11-20
1 year+1,200%USD 0.002024-10-03
3 year-87%USD 0.002022-09-06
5 year+1,200%USD 0.002020-10-19
Since inception-99.99%USD 0.252003-07-11

Dermisonics Financials at a Glance

Market Cap

$800.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$22.59M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-22.33 (Low)

Price

$0.00

Volume

765

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Nov 27, 2024

DMSI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dermisonics

Dermisonics, Inc. is a healthcare company specializing in the development and production of ultrasonic technologies for transdermal medication delivery. The company focuses on creating innovative solutions, including its flagship product, the U-Strip, designed for needle-free administration of large molecular weight drugs.

Products and Services
  • U-Strip: An active transdermal patch for drug delivery
  • Ultrasonic technology for enhanced medication absorption
  • Research and development in transdermal systems
Growth Outlook
  • Potential market expansion in the transdermal drug delivery sector
  • Increasing demand for needle-free drug administration solutions
  • Focus on innovative product development to capture market share
Financial Highlights
  • Recent quarterly net income of -$516,189, indicating ongoing operational challenges
  • Trailing twelve months (TTM) revenue remains at $0, reflecting early-stage development
  • Current ratio of 0.14, suggesting liquidity concerns
Dermisonics, Inc. operates in a niche market with significant growth potential, particularly in the realm of transdermal drug delivery. The U-Strip represents a unique offering that addresses the growing demand for non-invasive medication administration. Despite current financial challenges, including a negative net income and zero revenue, the company is positioned to leverage its innovative technologies to capture market opportunities. The focus on research and development may lead to future product launches that could enhance revenue streams. Investors may find interest in the company's potential to disrupt traditional drug delivery methods, especially as healthcare trends shift towards more patient-friendly solutions.
AI Generated • Jul 30, 2026

Industry

Healthcare Equipment and Supplies

Headquarters

Irvine, CA 92614, US

DMSI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-32.40%

Return on Capital

-23.95%

Return on Assets

-25.31%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$800.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

63.91M

Volume

765

Avg. Volume

0

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$22.02M

EBITDA

-$2.56M

Operating Cash Flow

-$669.36K

Capital Expenditure

$0.00

Free Cash Flow

-$672.37K

Cash & ST Invst.

$22.77K

Total Debt

$2.65M

Dermisonics Performance Analysis

Dermisonics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42006-09-30N/A
Q12006-12-31N/A
Q22007-03-31N/A
Q32007-06-30N/A
Dermisonics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42006-09-30-2.3%
Q12006-12-3134.9%
Q22007-03-31-1950.0%
Q32007-06-3097.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2007YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$800.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-$516.19K

+60.8%

EBITDA

-$414.15K

+64.4%

Quarterly Fundamentals

Name
Q3 2007YOY CHG

Total Cash

$22.77K

N/A

Total Debt

$2.65M

-26.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$2.22M

+19.0%

Short Term Debt

$433.14K

-74.9%

Return on Assets

-25.31%

N/A

Return on Invested Capital

-27.73%

N/A

Free Cash Flow

-$27.80K

+91.8%

Operating Cash Flow

-$27.80K

+91.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NMRDNemaura Medical Inc.
$0.00+0.00%
DNAGDNAPrint Genomics, Inc.
$0.00+0.00%
VICARafina Innovations Inc.
$0.00+0.00%
HESGHealth Sciences Group, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.83+0.06%
IBITiShares Bitcoin Trust
$41.21+0.06%
SPCXSpace Exploration Technologies
$131.46-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.73-0.05%

Questions About DMSI

What is the current price of Dermisonics?

Dermisonics is trading at $0.00 per share.

What is the 52-week range for Dermisonics?

Over the past 52 weeks, Dermisonics has traded between $0.00 and $0.00.

How much debt does Dermisonics have?

Dermisonics total debt is unavailable.

How much cash does Dermisonics have on hand?

Dermisonics does not have cash on hand data available.

What is Dermisonics’s dividend yield?

Dermisonics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.